company background image
QGEN logo

Qiagen NYSE:QGEN Stock Report

Last Price

US$43.57

Market Cap

US$9.7b

7D

-3.7%

1Y

4.3%

Updated

04 Oct, 2024

Data

Company Financials +

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

US$50.97
FV
14.5% undervalued intrinsic discount
7.17%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 days ago author updated this narrative

Qiagen N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Qiagen
Historical stock prices
Current Share PriceUS$43.57
52 Week HighUS$47.44
52 Week LowUS$35.81
Beta0.39
11 Month Change-1.34%
3 Month Change6.01%
1 Year Change4.33%
33 Year Change-17.25%
5 Year Change56.07%
Change since IPO2,052.60%

Recent News & Updates

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Recent updates

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio

Jul 15

Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Jun 29
Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Shareholder Returns

QGENUS Life SciencesUS Market
7D-3.7%-2.5%-0.7%
1Y4.3%15.4%32.5%

Return vs Industry: QGEN underperformed the US Life Sciences industry which returned 15.4% over the past year.

Return vs Market: QGEN underperformed the US Market which returned 32.5% over the past year.

Price Volatility

Is QGEN's price volatile compared to industry and market?
QGEN volatility
QGEN Average Weekly Movement3.3%
Life Sciences Industry Average Movement8.7%
Market Average Movement6.4%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: QGEN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: QGEN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19845,900Thierry Bernardwww.qiagen.com

Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

Qiagen N.V. Fundamentals Summary

How do Qiagen's earnings and revenue compare to its market cap?
QGEN fundamental statistics
Market capUS$9.68b
Earnings (TTM)US$72.70m
Revenue (TTM)US$1.94b

133.2x

P/E Ratio

5.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QGEN income statement (TTM)
RevenueUS$1.94b
Cost of RevenueUS$936.99m
Gross ProfitUS$1.00b
Other ExpensesUS$930.52m
EarningsUS$72.70m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.33
Gross Margin51.71%
Net Profit Margin3.75%
Debt/Equity Ratio42.8%

How did QGEN perform over the long term?

See historical performance and comparison